C-QAKXAltay Therapeutics
transcription factor inhibition, small molecules, allosteric sites
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-QAKX
C-QAKXC-QAKXtranscription factor inhibition, small molecules, allosteric sites
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Altay Biopharma states that it is developing targeted, curative therapies for metabolic diseases and that its approach uses regenerative medicine, implying a belief that regenerative medicine can enable disease-focused, potentially curative treatment strategies in metabolic disorders.
SourceAltay Therapeutics states that chronic inflammatory liver diseases, fibrotic diseases, and certain cancers can be treated by novel small-molecule drugs that inhibit key transcriptional regulators. The company believes these regulators are validated drivers of disease, that blocking their DNA-interacting domains can switch off target genes, and that this platform can produce safe and potent therapies across multiple chronic indications including NASH, IPF, rheumatoid arthritis, ulcerative colitis, and liver cancer.
SourceAltay Therapeutics states that chronic inflammatory diseases and cancers can be treated by developing small molecules that inhibit disease-causing transcription factors, including targets considered "undruggable," by disrupting their association with DNA. The company presents this as a novel, platform-driven approach for identifying new transcription factor targets and generating safe, potent therapies across multiple disease areas.
Source